Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ambrx Biopharma Inc ADR (NY: AMAM )

N/A UNCHANGED
Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ambrx Biopharma Inc ADR

< Previous 1 2 3 4 5 6 7 8 Next >
Ambrx Biopharma's Oncology Pipeline Is Underappreciated, Analyst Initiating Coverage Says
Cantor Fitzgerald initiated coverage on Ambrx Biopharma Inc (NASDAQ: AMAM) with an Overweight rating and a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 19, 2023
Via Benzinga
What 4 Analyst Ratings Have To Say About Ambrx Biopharma
Via Benzinga
Why Shares of Ambrx Biopharma Jumped This Week
The company reported data on its clinical programs at two conferences this week. 
Via The Motley Fool
Ambrx Biopharma Highlights Preclinical Data From Studies in Kidney, Prostate Cancer
Via Benzinga
Why Sunrise New Energy Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
$59M Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
Over $25M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
7 Cheap Stocks That Are Worth Your Attention
Finding cheap stocks that are worth an investment can be tricky, but the Portfolio Grader is a tool you can use to narrow the field. 
Via InvestorPlace
7 Risky Stocks That Are Worth the Stretch
If you're going to invest in risky stocks, it's important for you to first understand your risk tolerance. These names will get you started. 
Via InvestorPlace
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a... 
Via Benzinga
5 Short Squeeze Candidates To Watch: Ambrx Biopharma, Kala Pharmaceuticals And This Company That Moved Up 1,403 Positions
Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits... 
Via Benzinga
Ambrx Raises $78 Million and Completes its ATM Program
From Ambrx, Inc.
Via Business Wire
Week In Review: Sino Biopharma Acquires F-Star For $161 Million After US Approval
Sino Biopharma was approved to close its $161 million all-cash acquisition of F-Star. The purchase didn't look like would happen after it was held up for nine months by the US government’s Committee on... 
Via Talk Markets
Why Shares of Ambrx Biopharma Fell Tuesday
After getting a bump on Monday for its switch to the Nasdaq Stock Market, there was a bit of a correction. 
Via The Motley Fool
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Sheds Over 300 Points After Powell Comments
Federal Reserve Chair Jerome Powell's latest comments are dragging down sentiment on Wall Street. 
Via Talk Markets
Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate Buy 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Adial Pharmaceuticals Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Nutanix, Cara Therapeutics, Tremor International And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Tesla, Amazon, Ambrx, BridgeBio, Azul: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Ambrx to Commence Trading on Nasdaq
From Ambrx, Inc.
Via Business Wire
EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In February — Including Tesla, Apple And A Surging AI Name
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results
From Ambrx, Inc.
Via Business Wire
Top 5 Health Care Stocks That You May Want To Dump In Q1 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.